Tr1X, Inc. to highlight Miltenyi Biotec CDMO capabilities for scalable allogeneic cell therapy manufacturing at the 11th Annual CAR-TCR Summit

Published on 15 September 2026

San Diego, CA, and Bergisch Gladbach, Germany – September 15, 2026 – Tr1X, Inc. and Miltenyi Biotec today announced that they will highlight their collaboration to support the development and manufacturing of Tr1X’s allogeneic Tr1 and CAR-Tr1 Treg cell therapy programs at the 11th Annual CAR-TCR Summit, taking place September 15–17, 2026, in Boston, Massachusetts.

Explore posts connected to this topic

CIRM approves more than $60 million to support clinical and preclinical development awards

South San Francisco, CA, June 25, 2026 – The California Institute for Regenerative Medicine (CIRM) governing board today approved funding...

Press Releases

June 26, 2026

Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease

Press Releases

May 8, 2026

Bag of Tr1Xs: Off-the-Shelf Type 1 Treg Shows Phase I Promise for GvHD

In a clinical first, Tr1X Bio showed immune reconstitution and

Interviews

February 11, 2026

South San Francisco, CA, June 25, 2026 – The California

Press Releases

June 26, 2026